2seventy bio v Johnson & Johnson (CFI, 23 September 2026)
| Date | 23 September 2026 |
|---|---|
| Court | CFI |
| Division | Brussels (BE) Local Division |
| Type of action | Infringement Action |
| Case number(s) | UPC_CFI_29/2026 |
| Registry reference | UPC-CFI-0000029/2026 |
| Parties | 2seventy bio, Inc. v. Johnson & Johnson, Janssen Biotech, Inc., Janssen Pharmaceuticals Inc., Janssen-Cilag International NV, Janssen Pharmace… |
| Language | English |
Official decision (PDF) · UPC registry entry
Case timeline
- 15 June 2026 : 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) UPC-CFI-29/2026
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 19 October 2026
Our analysis
Summary
In this CAR-T life sciences infringement action, the Brussels Local Division dismissed the defendants’ Rule 190 RoP applications for production of evidence directed at documents of the NIH (laboratory notebooks, invention reports, grant files, notice records), rejected the NIH’s request to be reclassified from intervener to co-claimant in the infringement action, and reserved costs. The court held that a Rule 190 order requires, among cumulative conditions, that the underlying claims be plausible on the basis of reasonably available evidence, a threshold the defendants’ entitlement-based challenge to 2seventy bio’s standing did not meet at this stage.
Why it matters
The order, published with seven official headnotes, gives structured guidance on three recurring questions. First, on intervention: the Rules of Procedure do not allow interventions in which the intervener directs claims against other parties, and a counterclaim for revocation makes the intervening patent holder a defendant to that counterclaim without making it a co-claimant in the infringement action. Second, on Rule 8.4 RoP: the fiction that the registered proprietor is treated as proprietor applies, in the court’s words, “only for the application of the RoP and more specifically the administrative tasks to be performed by the Court”, so that entitlement may be raised as a substantive defence and the presumption is rebuttable. Third, on Article 47 UPCA: prior notice to the proprietor is assessed at the date the action is recorded in the register and the burden of proving compliance lies on the claimant. The practical consequence is that defendants cannot use Rule 190 as a discovery tool to build a speculative entitlement defence, while licensees suing under Article 47 must document prior notice before filing.
Practical point
Exclusive licensees preparing UPC actions should assemble contemporaneous proof of prior notice to the proprietor before lodging the Statement of claim, since later production requests aimed at the proprietor’s files will not cure a standing gap.
Summary prepared by Dhenne Avocats. Only the official text of the decision is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- English from the language of proceedings
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimant2seventy bio, Inc.4 decisions in the corpusFollow this party
- defendantJohnson & Johnson4 decisions in the corpusFollow this party
- defendantJanssen Biotech, Inc.5 decisions in the corpusFollow this party
- defendantJanssen Pharmaceuticals Inc.4 decisions in the corpusFollow this party
- defendantJanssen-Cilag International NV4 decisions in the corpusFollow this party
- defendantJanssen Pharmace4 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 15 June 2026 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) Infringement Action · UPC_CFI_29/2026
Avec l'accord des parties, la division locale de Bruxelles instruit ensemble l'action en contrefaçon et les demandes reconventionnelles en nullité, et un juge technicien sera demandé.
- 23 September 2026 2seventy bio v Johnson & Johnson (CFI, 23 September 2026) Infringement Action · UPC_CFI_29/2026
What the record states
- Nature of the act
- Infringement Action
- Outcome (Dhenne Avocats summary)
- In this CAR-T life sciences infringement action, the Brussels Local Division dismissed the defendants' Rule 190 RoP applications for production of evidence directed at documents of the NIH (laboratory notebooks, invention reports, grant files, notice records), rejected the NIH's request to be reclassified from intervener to co-claimant in the infringement action, and reserved costs. The court held that a Rule 190 order requires, among cumulative conditions, that the underlying claims be plausible on the basis of reasonably available evidence, a threshold the defendants' entitlement-based challenge to 2seventy bio's standing did not meet at this stage.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Related decisions cited in the analyses
- 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) cited in this record
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.